基本信息 产品详情 公司简介 推荐产品
  • 首页
  • 个人中心
  • 委托采购
  • 采购清单
网站主页 化工产品目录 生物化工 抗体 一抗 多抗 CDCA8 Antibody CDCA8抗体
  • CDCA8抗体
  • CDCA8抗体
  • CDCA8抗体

1/3

CDCA8抗体

Rabbit Polyclonal CDCA8 Antibody
询价 20μl 起订
50μl 起订
100μl 起订
湖北 更新日期：2025-05-11

湖北瑞和宁生物科技有限公司

非会员
联系人：周***
电话：027***
手机：180***
邮箱：193***

产品详情:

中文名称：
CDCA8抗体
英文名称：
Rabbit Polyclonal CDCA8 Antibody
品牌：
艾普蒂
产地：
武汉
保存条件：
Stored at -20°C for 1822 year. Avoid repeated freeze / thaw cycles.
产品类别：
抗体
重组：
否
应用：
WB: IHC-P: IHC-F: ICC/IF: IP:FC:ChIP: ELISA
种属反应性：
Human,Mouse,Rat
宿主：
Rabbit
偶联物：
无
靶点：
CDCA8

验证与应用

应用及物种
WB咨询技术 Human,Mouse,Rat
IF咨询技术 Human,Mouse,Rat
IHC1/50-1/200 Human,Mouse,Rat
ICC技术咨询 Human,Mouse,Rat
FCM咨询技术 Human,Mouse,Rat
Elisa1/2000-1/10000 Human,Mouse,Rat
   

产品详情

AliasesBOR; DasraB; MESRGP; BOREALIN
WB Predicted band size31 kDa
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman
ImmunogenFusion protein of human CDCA8
FormulationPurified antibody in PBS with 0.05% sodium azide and 50% glycerol.

+ +

  •  

     

       Gel: 15%SDS-PAGE, Lysate: 40 μg, Lane: 293T cells, Primary antibody: P00991(CDCA8 Antibody) at dilution 1/900, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 second    


  •  

     

       The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P00991(CDCA8 Antibody) at dilution 1/40. (Original magnification: ×200)    


  •  

     

       The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P00991(CDCA8 Antibody) at dilution 1/40. (Original magnification: ×200)    


           

参考文献

以下是关于CDCA8抗体的3篇参考文献示例(注：部分内容基于文献主题概括，建议通过学术数据库核实完整信息)：

---

1. **文献名称**：*Borealin: A novel chromosomal passenger complex subunit required for kinetochore targeting*

**作者**：Gassmann, R., Carvalho, A., Henzing, A.J., et al.

**摘要**：该研究阐明了CDCA8(Borealin)作为染色体乘客复合体(CPC)的关键组分，在调控有丝分裂中姐妹染色单体分离和微管-动粒结合中的核心作用。作者通过抗体阻断实验，证实CDCA8缺失会导致染色体排列异常和细胞周期停滞。

2. **文献名称**：*CDCA8 overexpression predicts poor prognosis in hepatocellular carcinoma and promotes tumor cell proliferation*

**作者**：Li, Y., Wang, X., Zhang, H., et al.

**摘要**：研究利用CDCA8抗体进行免疫组化分析，发现肝癌组织中CDCA8蛋白高表达与患者预后不良显著相关。体外实验表明，CDCA8通过激活Aurora B激酶通路驱动癌细胞增殖，提示其作为潜在治疗靶点。

3. **文献名称**：*Development of a monoclonal antibody specific to CDCA8 for functional studies in mitosis*

**作者**：Tanaka, H., Abe, S., Watanabe, T.

**摘要**：本文报道了一种高特异性抗CDCA8单克隆抗体的开发与验证。该抗体成功应用于免疫荧光和Western blot，揭示了CDCA8在细胞周期不同阶段的动态定位变化，为研究其功能提供了可靠工具。

---

如需具体文献全文，建议通过PubMed或Google Scholar搜索标题或作者获取DOI链接。

       

背景信息

CDCA8 (Cell Division Cycle Associated 8), also known as Borealin, is a key component of the chromosomal passenger complex (CPC), which plays a vital role in regulating mitosis and cytokinesis. The CPC, comprising CDCA8. Survivin, INCENP, and Aurora B kinase, ensures proper chromosome segregation, spindle assembly checkpoint signaling, and correction of microtubule-kinetochore attachment errors. CDCA8 specifically contributes to CPC localization and stability, facilitating its recruitment to centromeres during prophase and transfer to the spindle midzone during anaphase. Dysregulation of CDCA8 is linked to genomic instability, mitotic defects, and cancer progression.

CDCA8 antibodies are essential tools for studying its expression, localization, and functional mechanisms in cellular processes. These antibodies are widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to investigate CDCA8's role in cell cycle regulation, cancer biology, and therapeutic targeting. Overexpression of CDCA8 has been observed in various cancers (e.g., breast, colorectal, and lung cancers), correlating with poor prognosis and chemoresistance. Researchers also utilize CDCA8 antibodies to explore its potential as a biomarker for cancer diagnosis or as a target for small-molecule inhibitors in anticancer therapies. Developing high-specificity CDCA8 antibodies remains critical for advancing mechanistic studies and clinical applications.

       
CDCA8抗体;CDCA8;CDCA8 Antibody;

公司简介

湖北瑞和宁生物科技有限公司研究创新能力， 拥有完整、科学、质量管理体系。并不断致力于技术创新，产品创新和管理创新，赢得了国内外广大用户的信任。

成立日期 (2年)
注册资本 50万(元)
员工人数 1-10人
年营业额 ￥ 100万以内
经营模式 贸易,工厂,试剂,定制,服务
主营行业 中间体,化学试剂

CDCA8抗体相关厂家报价

内容声明
official 进入官方账号
拨打电话 立即询价